Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) finished Friday with an addition of $0.08 to close at $40.83, an upside of 0.20 percent. An average of 2,328,920 shares of common stock have been traded in the last five days. There was a gain of $1.43 in the past week, and it reached a new high 8 times over the past 12 months. The last 20 days have seen an average of 801,490 shares traded, while the 50-day average volume stands at 583,660.
HRMY stock has increased by 5.94% in the last month. The company shares reached their 1-month lowest point of $35.08 on 10/12/21. With the stock rallying to its 52-week high on 10/19/21, shares of the company touched a low of $25.09 and a high of $52.74 in 52 weeks. It has reached a new high 7 times so far this year and achieved 12.95% or $4.68 in price. In spite of this, the price is down -22.58% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
4 days have passed since Harmony Biosciences Holdings Inc. (HRMY) last reported insider trading activity. Dayno Jeffrey M., who is Chief Medical Officer, most recently acquired $18,200 shares at $43.27 per share on Oct 19. In this transaction, the insider spent $787,543. Chief Medical Officer, Dayno Jeffrey M., disposed of 1,800 shares at a price of $40.10 on Oct 06. The insider now owns more than $72,179 worth of shares. Prior to that, President, CEO Jacobs John C went on to Sale 25,000 shares at $35.93 each on Sep 13. An amount of $898,262 was transacted.
Harmony Biosciences Holdings Inc. (HRMY) has a trailing price-to-earnings (P/E) ratio of 140.31, which compares with the 34.65 for the broader industry and 33.43 for the sector. In the last five years, Harmony Biosciences Holdings Inc.’s PE ratio has ranged between 185.44 and 113.44. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 9.65, the price-to-book (PB) ratio at 18.39, and the price-to-cash flow ratio at 46.06.
The quick ratio of Harmony Biosciences Holdings Inc. for the three months ended June 29 was 5.50, and the current ratio was 5.60, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 1.55 and a total debt to equity ratio of 1.55 for the quarter ending June 29. Harmony Biosciences Holdings Inc.’s EBITDA margin for the year ending June 29 is 17.04%, while its operating margin for the same period stands at 23.80%. Its gross profit as reported stood at $132.0 million compared to revenue of $159.74 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Harmony Biosciences Holdings Inc.’s return on assets was 4.80%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Harmony Biosciences Holdings Inc. had $195.61 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of $14.12 million in the quarter, while revenues of $7.39 million were grew 100.0%. The analyst consensus anticipated Harmony Biosciences Holdings Inc.’s latest quarter earnings to come in at $0.18 per share, but it turned out to be $0.24, a 33.30% surprise. For the quarter, EBITDA amounted to $28.74 million. Shareholders own equity worth $57.01 million.
From a technical analysis perspective, let’s take a brief look at Harmony Biosciences Holdings Inc. (HRMY) price momentum. RSI 9-day as of the close on 22 October was 60.71%, suggesting the stock is Neutral, with historical volatility in this time frame at 57.21%.
As of today, HRMY’s price is $40.70 +3.63% or $1.43 from its 5-day moving average. HRMY is currently trading +8.48% higher than its 20-day SMA and +26.68% higher than its 100-day SMA. However, the stock’s current price level is +28.64% above the SMA50 and +11.74% above the SMA200.
The stochastic %K and %D were 66.32% and 68.21%, respectively, and the average true range (ATR) was 2.07. With the 14-day stochastic at 62.45% and the average true range at 2.02, the RSI (14) stands at 59.76%. The stock has reached 1.79 on the 9-day MACD Oscillator while the 14-day reading was at 2.51.
Needham launched coverage on Harmony Biosciences Holdings Inc. (NASDAQ: HRMY) in its analyst report released on September 23, 2021. The firm assigned the stock a a Buy rating. The consensus rating for Harmony Biosciences Holdings Inc. (HRMY) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell HRMY, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is HRMY’s price target for the next 12 months?
Analysts predict a range of price targets between $43.00 and $57.00, with a median target of $55.50. Taking a look at these predictions, the average price target given by analysts for Harmony Biosciences Holdings Inc. (HRMY) stock is $52.75.